Shaji Kumar, MD, a hematologist at the Mayo Clinic and chair of the Plasma Cell Disorders Scientific Committee at the American Society of Hematology, discuses the standard of care in newly diagnosed myeloma.
Shaji Kumar, MD, a hematologist at the Mayo Clinic and chair of the Plasma Cell Disorders Scientific Committee at the American Society of Hematology, discuses the standard of care in newly diagnosed myeloma.
According to Kumar, the standard of care is currently a proteasome inhibitor in combination with immunomodulatory drugs or monoclonal antibodies. For patients who are transplant-eligible, induction therapy with dexamethasone is used prior to a single transplant. After the transplant, patients received lenalidomide maintenance (Revlimid). If that patient is high-risk, daratumumab (Darzalex) plus bortezomib, lenalidomide, dexamethasone (VRd) is used.
If the patient is ineligible for transplant, daratumumab is used until disease progression. For high-risk disease, VRd light is used with an effort to also use a proteasome inhibitor or other immunomodulatory drug.
0:08 | The current treatments that we use for newly diagnosed myeloma, are essentially combinations of proteasome inhibitors, immunomodulatory drugs or monoclonal antibodies. Patients who are eligible for a stem cell transplant often get induction therapy with dexamethasone, has a single transplant and goes on lenalidomide maintenance. If they are high risk, we try to use 4 drug combinations, including daratumumab plus VRd, then onto single or 2 transplants and then to drug maintenance therapy. Non transplant eligible patients get started with daratumumab and often continue on therapy until progression. In people with high risk disease, we tend to use VRd light, but typically try to get a proteasome inhibitor and immunomodulatory drug in there.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More